Epstein-Barr virus and lymphoproliferative disease.
Epstein-Barr virus and lymphoproliferative disease.
复制标题
Epstein-Barr 病毒和淋巴组织增生性疾病。
DOI：
10.1097/00062752-199901000-00005
复制
发表时间：
1999
期刊：
影响因子：
--
通讯作者：
Mosier,DE
中科院分区：
文献类型：
--
作者：
Mosier,DE
EB病毒是一种普遍存在的人类疱疹病毒，与越来越多的人类恶性肿瘤有关。其中包括免疫功能低下患者中的EB病毒相关淋巴增生性疾病，这是一系列主要是B细胞疾病，范围从多克隆淋巴增生性疾病（当免疫抑制停止时消退）到高度恶性淋巴瘤。进展已经确定了参与B细胞转化的EB病毒基因产物、EB病毒转化基因的变异、具有EB病毒表达的不同调节的不同靶细胞群体以及选择性募集其他支持细胞类型作为淋巴组织增生性疾病异质性的因素。治疗淋巴增生性疾病的新的治疗方法也正在开发中。最后，异种移植带来了新的风险，在严重免疫抑制的患者中引入EB病毒样病毒和更具侵袭性的淋巴组织增生性疾病。
The Epstein-Barr virus is a ubiquitous human herpesvirus that is associated with an increasing number of human malignancies. Among these are Epstein-Barr virus-associated lymphoproliferative diseases in immunocompromised patients, a spectrum of mainly B-cell diseases that range from polyclonal lymphoproliferative diseases, which resolve when immunosuppression is halted, to highly malignant lymphomas. Progress has identified Epstein-Barr virus gene products involved in B-cell transformation, variation in Epstein-Barr virus transforming genes, distinct target cell populations with differing regulation of Epstein-Barr virus expression, and selective recruitment of other supportive cell types as factors in the heterogeneity of lymphoproliferative diseases. New therapeutic approaches to treat lymphoproliferative diseases are also being developed. Finally, xenotransplantation poses new risks for the introduction of Epstein-Barr virus-like viruses and more aggressive lymphoproliferative diseases in heavily immunosuppressed patients.